Integrated Photothermal‐Pyroelectric Biosensor for Rapid and Point‐of‐Care Diagnosis of Acute Myocardial Infarction: A Convergence of Theoretical Research and Commercialization
Acute myocardial infarction (AMI) survivors face a high risk of mortality as a result of increasing heart failure and irreparable myocardial injury. New portable methods for immediate diagnosis must be developed to provide patients with daily warnings. Herein, the development of a dual‐mode photothe...
Gespeichert in:
Veröffentlicht in: | Small (Weinheim an der Bergstrasse, Germany) Germany), 2022-07, Vol.18 (30), p.e2202564-n/a |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Acute myocardial infarction (AMI) survivors face a high risk of mortality as a result of increasing heart failure and irreparable myocardial injury. New portable methods for immediate diagnosis must be developed to provide patients with daily warnings. Herein, the development of a dual‐mode photothermal‐pyroelectric output system based on a point‐of‐care platform for rapid AMI detection is reported. Termed as Integrated Photothermal‐Pyroelectric Biosensor for AMI (IPPBA), the method leverages cascade enzymatic amplification to convert the target signal into a thermal and pyrooelectric conversion of the testing process by delicate pyroelectric pervokite NaNbO3 nanocubes modified microelectrodes for sensitive detection of cTnI protein in whole blood. In addition, the mechanism of the proposed pyroelectric bioassay model is explored in depth based on in situ variable temperature X‐ray diffraction (XRD) lattice change statistics and density function theory (DFT) calculations. With standard samples and under optimized experimental conditions, the proposed IPPBA platform exhibits excellent signal stability and ultra‐low detection limit (0.05 ng mL–1) for the target cTn I. With further developments in digital technology (e.g., 5G signaling protocols, fully automated systems), the integrated digital bio‐testing platform IPPBA is fully capable of accomplishing positive and timely diagnosis of AMI.
An integrated photothermal‐pyroelectric biosensor for acute myocardial infarction system is designed for efficient and sensitive quantification of cTnI protein in various environments. Strategies for cascade enzymatic reaction and efficient photo‐thermo‐electric conversion are proposed and validated. This system has promise for practical applications in the prognostic analysis and staging assessment of AMI in the future. |
---|---|
ISSN: | 1613-6810 1613-6829 |
DOI: | 10.1002/smll.202202564 |